Next-Generation CAR T Cell Therapies Market

Global Next-Generation CAR T Cell Therapies Market Size, Trends & Analysis - Forecasts to 2029 By Type of Therapy (Allogeneic Therapies, Autologous Therapies, and Others), By Targeted Indications (Hematologic Malignancies and Solid Tumors), By Development Phase (Preclinical, Clinical (Phase I, II, III), and Commercialized), and By Region (North America, Asia Pacific, Central and South America, Europe, and Middle East and Africa), Competitive Landscape, Company Market Share Analysis, and End User Analysis

Category Healthcare
Format
  • ms word
  • ms excel
  • ms ppt
  • pdf
This report was recently updated on June 8 2024 with the latest and most recent market numbers

Global Next-Generation CAR T Cell Therapies Market Size

The global next-generation CAR T cell therapies market is projected to grow at a CAGR of 33.1% from 2024 to 2029.

The rising global prevalence of cancer is a major factor driving the demand for next-generation CAR T cell therapies. These medicines are being studied to treat various cancers, including hematologic malignancies and solid tumors. Their potential for focused treatment and perhaps improved results have piqued the medical community's interest as a promising route for cancer therapy in light of the disease's expanding worldwide burden.

Next-generation CAR T cell treatments represent a significant advancement in immunotherapy. Compared to standard treatments such as chemotherapy and radiation therapy, they exhibit refined targeting, increased efficacy, and potentially improved safety profiles. This novel strategy involves using the patient's immune cells to battle cancer, representing a substantial advancement in treatment options. With greater precision and the possibility of reducing off-target effects, these medicines offer a viable option for treating previously tough cancer types. Their study highlights a significant advancement in cancer therapy options, providing patients with a potentially more effective and comfortable therapeutic alternative.

Pharmaceutical corporations, biotechnology firms, and academic institutions are investing extensively in R&D to improve the efficacy and usability of CAR T cell therapy. These investments spur research and accelerate the development of next-generation medicines.

CAR T cell therapies have significant production and treatment costs, which make them financially difficult for healthcare systems and patients. Reimbursement and price constraints may limit access to these treatments.

global next-generation car t cell therapies market

Global Next-Generation CAR T Cell Therapies Market: By Type of Therapy

The allogeneic therapies segment is expected to hold the largest share in the market. Allogeneic medicines are available off the shelf, eliminating the need for patient-specific manufacture and shortening treatment times. Furthermore, they offer broader applicability, cheaper production costs, and possible scalability, making them more appealing from a commercial and logistical aspect than autologous treatments.

The autologous therapies segment is expected to be the fastest-growing segment in the market from 2024 to 2029. Autologous therapies use the patient's immune cells, reducing the risk of rejection and graft-versus-host disease. Furthermore, advances in manufacturing technology are expediting the production process, increasing scalability, and lowering prices, hence driving adoption. Additionally, tailored therapeutic approaches are gaining traction, contributing to the rising demand for autologous therapies.

Global Next-Generation CAR T Cell Therapies Market: By Targeted Indications

The solid tumors segment is anticipated to be the fastest-growing segment in the market from 2024 to 2029. Advances in CAR T cell engineering, such as dual-targeting techniques and overcoming the immunosuppressive tumor microenvironment, improve the efficacy of CAR T cell therapy in solid tumors. Furthermore, clinical trials examining CAR T cell treatments in multiple solid tumor types yield promising results, raising expectations for their widespread acceptance in this segment.

The hematologic malignancies segment is expected to hold the largest share of the market. CAR T cell treatments have shown substantial success in treating hematologic malignancies such as lymphoma, leukemia, and multiple myeloma. Furthermore, these indications frequently provide a more favorable tumor milieu for CAR T cell therapy delivery and are linked with greater response rates than solid tumors, which drives the preference for CAR T cell treatment in hematologic malignancies.

Global Next-Generation CAR T Cell Therapies Market: By Development Phase

The commercialized segment is anticipated to be the fastest-growing segment in the market from 2024 to 2029. The expected growth of the segment is driven by an increase in the number of products receiving approval from regulatory agencies. Additionally, growing recognition of these treatments' safety, effectiveness, and therapeutic value also contributes to the segment's growth. As regulatory bodies continue to approve more T-cell therapies for a wide range of indications, including both hematologic malignancies and solid tumors, the market is poised for significant expansion. This development signifies a notable progression towards broader acceptance and utilization of these therapies, offering enhanced treatment options for patients across different cancer types.

asia pacific next-generation car t cell therapies market

Global Next-Generation CAR T Cell Therapies Market: By Region

North America is expected to be the largest region in the market. The primary reasons boosting the market growth in this region include factors such as robust research infrastructure, significant healthcare spending, and a favorable regulatory environment. Furthermore, the region has a significant presence of key market competitors as well as a high cancer prevalence, all of which contribute to North America's market dominance.

Asia Pacific is predicted to witness rapid growth during the forecast period. The regional market growth is attributed to the growing healthcare costs, increased cancer prevalence, and improved healthcare infrastructure. Furthermore, increased collaboration between global pharmaceutical corporations and local firms is accelerating the development and implementation of next-generation CAR T cell therapies in the region.

Global Next-Generation CAR T Cell Therapies Market Share and Competitor Analysis

Novartis, Kite Pharma (Tmunity Therapeutics), Bluebird bio, Bristol Myers Squibb, Atara Biotherapeutics, Allogene Therapeutics, Autolus Therapeutics, Precision Biosciences, Inc., Celyad Oncology, and Cellectis., among others, are some of the key players operating in the global next-generation CAR T cell therapies market.

Please note: This is not an exhaustive list of companies profiled in the report.

Global Next-Generation CAR T Cell Therapies Market: Recent Developments

In February 2023, Kite Pharma, a Gilead Company,  finalized its acquisition of Tmunity Therapeutics, enhancing its CAR T-cell therapy portfolio. The acquisition bolsters Kite's research capabilities, adding pipeline assets, platform technologies, and a strategic collaboration with the University of Pennsylvania. Tmunity's 'armored' CAR T platform and rapid manufacturing processes complement Kite's efforts in advancing cell therapies.

1          STRATEGIC INSIGHTS ON NEW REVENUE POCKETS

1.1    Strategic Opportunity & Attractiveness Analysis

1.1.1        Hot Revenue Pockets

1.1.2        Market Attractiveness Score

1.1.3        Revenue Impacting Opportunity

1.1.4        High Growing Region/Country

1.1.5        Competitor Analysis

1.1.6        Consumer Analysis

1.2    Global Market Estimates' View

1.3    Strategic Insights across Business Functions

1.3.1        For Chief Executive Officers

1.3.2        For Chief Marketing Officers

1.3.3        For Chief Strategy Officers

1.4    Evaluate the Potential of your Existing Business Lines vs. New Lines to Enter Into

2          TECHNOLOGICAL TRENDS

2.1   Technological Adoption Rate

2.2   Current Trend Impact Analysis

2.3   Future Trend Impact Analysis

3          GLOBAL MARKET  OUTLOOK

3.1   Market Pyramid Analysis

3.1.1        Introduction

3.1.2           Adjacent Market Opportunities

3.1.3           Ancillary Market Opportunities

3.2   Demand Side Analysis

3.2.1           Market Drivers: Impact Analysis

3.2.2           Market Restraints: Impact Analysis

3.2.3           Market Opportunities: Impact Analysis

3.2.4           Market Challenges: Impact Analysis

3.3   Supply Side Analysis

3.3.1           Porter’s Five Forces Analysis

3.3.1.1 Threat of New Entrants

3.3.1.2 Threat of New Substitutes

3.3.1.3 Bargaining Power of Suppliers

3.3.1.4 Bargaining Power of Buyers

3.3.1.5 Intensity of Competitive Rivalry

3.3.2           SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)

3.3.2.1 Political Landscape

3.3.2.2 Economic Landscape

3.3.2.3 Social Landscape

3.3.2.4 Development Phase Landscape

3.3.3        Value Chain Analysis

3.3.4        Trend Analysis

3.3.5        Gap Analysis

3.3.6        Cost Analysis

4          GLOBAL NEXT-GENERATION CAR T CELL THERAPIES MARKET, BY TYPE OF THERAPY

4.1   Introduction

4.2   Next-Generation CAR T Cell Therapies Market: Type of Therapy Scope Key Takeaways

4.3   Revenue Growth Analysis, 2023 & 2029

4.4   Allogeneic Therapies

4.4.1           Allogeneic Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

4.5   Autologous Therapies

4.5.1           Autologous Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

4.6   Others

4.6.1           Others Market Estimates and Forecast, 2021-2029 (USD Million)

5          GLOBAL NEXT-GENERATION CAR T CELL THERAPIES MARKET, BY TARGETED INDICATIONS

5.1   Introduction

5.2   Next-Generation CAR T Cell Therapies Market: Targeted Indications Scope Key Takeaways

5.3   Revenue Growth Analysis, 2023 & 2029

5.4   Hematologic Malignancies

5.4.1           Hematologic Malignancies Market Estimates and Forecast, 2021-2029 (USD Million)

5.5   Solid Tumors

5.5.1           Solid Tumors Market Estimates and Forecast, 2021-2029 (USD Million)

6          GLOBAL NEXT-GENERATION CAR T CELL THERAPIES MARKET, BY DEVELOPMENT PHASE

6.1   Introduction

6.2   Next-Generation CAR T Cell Therapies Market: Development Phase Scope Key Takeaways

6.3   Revenue Growth Analysis, 2023 & 2029

6.4   Preclinical

6.4.1           Preclinical Market Estimates and Forecast, 2021-2029 (USD Million)

6.5    Clinical (Phase I, II, III)

6.5.1            Clinical (Phase I, II, III) Market Estimates and Forecast, 2021-2029 (USD Million)

6.6    Commercialized

6.6.1            Commercialized Market Estimates and Forecast, 2021-2029 (USD Million)

7          GLOBAL NEXT-GENERATION CAR T CELL THERAPIES MARKET, BY REGION

7.1   Introduction

7.2   North America Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.2.1        By Type of Therapy

7.2.2        By Targeted Indications

7.2.3        By Development Phase

7.2.4        By Country

7.2.4.1     U.S. Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.2.4.1.1        By Type of Therapy  

7.2.4.1.2        By Targeted Indications

7.2.4.1.3        By Development Phase

7.2.4.2     Canada Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.2.4.2.1        By Type of Therapy  

7.2.4.2.2        By Targeted Indications

7.2.4.2.3        By Development Phase

7.2.4.3     Mexico Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.2.4.3.1        By Type of Therapy  

7.2.4.3.2        By Targeted Indications

7.2.4.3.3        By Development Phase

7.3   Europe Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.3.1        By Type of Therapy  

7.3.2        By Targeted Indications

7.3.3        By Development Phase

7.3.4        By Country

7.3.4.1     Germany Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.3.4.1.1        By Type of Therapy  

7.3.4.1.2        By Targeted Indications

7.3.4.1.3        By Development Phase

7.3.4.2     U.K. Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.3.4.2.1        By Type of Therapy  

7.3.4.2.2        By Targeted Indications

7.3.4.2.3        By Development Phase

7.3.4.3     France Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.3.4.3.1        By Type of Therapy  

7.3.4.3.2        By Targeted Indications

7.3.4.3.3        By Development Phase

7.3.4.4     Italy Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.3.4.4.1        By Type of Therapy  

7.3.4.4.2        By Targeted Indications

7.2.4.4.3        By Development Phase

7.3.4.5     Spain Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.3.4.5.1        By Type of Therapy  

7.3.4.5.2        By Targeted Indications

7.2.4.5.3        By Development Phase

7.3.4.6     Netherlands Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.3.4.6.1        By Type of Therapy  

7.3.4.6.2        By Targeted Indications

7.2.4.6.3        By Development Phase

7.3.4.7     Lithuania Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.3.4.7.1        By Type of Therapy  

7.3.4.7.2        By Targeted Indications

7.2.4.7.3        By Development Phase

7.3.4.8     Estonia Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.3.4.8.1        By Type of Therapy  

7.3.4.8.2        By Targeted Indications

7.2.4.8.3        By Development Phase

7.3.4.9     Finland Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.3.4.9.1        By Type of Therapy  

7.3.4.9.2        By Targeted Indications

7.2.4.9.3        By Development Phase

7.3.4.10  Switzerland Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.3.4.10.1      By Type of Therapy  

7.3.4.10.2      By Targeted Indications

7.2.4.10.3      By Development Phase

7.3.4.11  Belgium Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.3.4.11.1      By Type of Therapy  

7.3.4.11.2      By Targeted Indications

7.2.4.11.3      By Development Phase

7.3.4.12  Poland Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.3.4.12.1      By Type of Therapy  

7.3.4.12.2      By Targeted Indications

7.2.4.12.3      By Development Phase

7.3.4.13  Ukraine Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.3.4.13.1      By Type of Therapy  

7.3.4.13.2      By Targeted Indications

7.2.4.13.3      By Development Phase

7.3.4.14  Sweden Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.3.4.14.1      By Type of Therapy  

7.3.4.14.2      By Targeted Indications

7.2.4.14.3      By Development Phase

7.3.4.15  Norway Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.3.4.15.1      By Type of Therapy  

7.3.4.15.2      By Targeted Indications

7.2.4.15.3      By Development Phase

7.3.4.16  Denmark Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.3.4.16.1      By Type of Therapy  

7.3.4.16.2      By Targeted Indications

7.2.4.16.3      By Development Phase

7.3.4.17  Rest of Europe Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.3.4.17.1      By Type of Therapy  

7.3.4.17.2      By Targeted Indications

7.2.4.17.3      By Development Phase

7.4   Asia Pacific Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.4.1        By Type of Therapy  

7.4.2        By Targeted Indications

7.4.3        By Development Phase

7.4.4        By Country

7.4.4.1     China Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.4.4.1.1        By Type of Therapy  

7.4.4.1.2        By Targeted Indications

7.4.4.1.3        By Development Phase

7.4.4.2     Japan Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.4.4.2.1        By Type of Therapy  

7.4.4.2.2        By Targeted Indications

7.4.4.2.3        By Development Phase

7.4.4.3     India Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.4.4.3.1        By Type of Therapy  

7.4.4.3.2        By Targeted Indications

7.4.4.3.3        By Development Phase

7.4.4.4     South Korea Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.4.4.4.1        By Type of Therapy  

7.4.4.4.2        By Targeted Indications

7.4.4.4.3        By Development Phase

7.4.4.5     Singapore Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.4.4.5.1        By Type of Therapy  

7.4.4.5.2        By Targeted Indications

7.4.4.5.3        By Development Phase

7.4.4.6     Malaysia Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.4.4.6.1        By Type of Therapy  

7.4.4.6.2        By Targeted Indications

7.4.4.6.3        By Development Phase

7.4.4.7     Thailand Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.4.4.7.1        By Type of Therapy  

7.4.4.7.2        By Targeted Indications

7.4.4.7.3        By Development Phase

7.4.4.8     Indonesia Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.4.4.8.1        By Type of Therapy  

7.4.4.8.2        By Targeted Indications

7.4.4.8.3        By Development Phase

7.4.4.9     Vietnam Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.4.4.9.1        By Type of Therapy  

7.4.4.9.2        By Targeted Indications

7.4.4.9.3        By Development Phase

7.4.4.10  Taiwan Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.4.4.10.1 By Type of Therapy  

7.4.4.10.2 By Targeted Indications

7.4.4.10.3 By Development Phase

7.4.4.11  Rest of Asia Pacific Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.4.4.11.1 By Type of Therapy  

7.4.4.11.2 By Targeted Indications

7.4.4.11.3 By Development Phase

7.5   Middle East and Africa Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.5.1        By Type of Therapy  

7.5.2        By Targeted Indications

7.5.3        By Development Phase

7.5.4        By Country

7.5.4.1     Saudi Arabia Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.5.4.1.1        By Type of Therapy  

7.5.4.1.2        By Targeted Indications

7.5.4.1.3        By Development Phase

7.5.4.2     U.A.E. Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.5.4.2.1        By Type of Therapy  

7.5.4.2.2        By Targeted Indications

7.5.4.2.3        By Development Phase

7.5.4.3     Israel Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.5.4.3.1        By Type of Therapy  

7.5.4.3.2        By Targeted Indications

7.5.4.3.3        By Development Phase

7.5.4.4     South Africa Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.5.4.4.1        By Type of Therapy  

7.5.4.4.2        By Targeted Indications

7.5.4.4.3        By Development Phase

7.5.4.5     Rest of Middle East and Africa Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.5.4.5.1        By Type of Therapy  

7.5.4.5.2        By Targeted Indications

7.5.4.5.2        By Development Phase

7.6   Central and South America Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.6.1        By Type of Therapy  

7.6.2        By Targeted Indications

7.6.3        By Development Phase

7.6.4        By Country

7.6.4.1     Brazil Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.6.4.1.1        By Type of Therapy  

7.6.4.1.2        By Targeted Indications

7.6.4.1.3        By Development Phase

7.6.4.2     Argentina Eaporative Air Cooler Market Estimates and Forecast, 2021-2029 (USD Million)

7.6.4.2.1        By Type of Therapy  

7.6.4.2.2        By Targeted Indications

7.6.4.2.3        By Development Phase

7.6.4.3     Chile Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.6.4.3.1        By Type of Therapy  

7.6.4.3.2        By Targeted Indications

7.6.4.3.3        By Development Phase

7.6.4.4     Rest of Central and South America Next-Generation CAR T Cell Therapies Market Estimates and Forecast, 2021-2029 (USD Million)

7.6.4.4.1        By Type of Therapy  

7.6.4.4.2        By Targeted Indications

7.6.4.4.3        By Development Phase

8          COMPETITIVE LANDCAPE

8.1   Company Market Share Analysis

8.2   Four Quadrant Positioning Matrix

8.2.1        Market Leaders

8.2.2        Market Visionaries

8.2.3        Market Challengers

8.2.4        Niche Market Players

8.3   Vendor Landscape

8.3.1        North America

8.3.2        Europe

8.3.3        Asia Pacific

8.3.4        Rest of the World

8.4   Company Profiles  

8.4.1        Novartis

8.4.1.1 Business Description & Financial Analysis

8.4.1.2 SWOT Analysis

8.4.1.3 Products & Services Offered

8.4.1.4 Strategic Alliances between Business Partners

8.4.2        Kite Pharma (Tmunity Therapeutics)

8.4.2.1 Business Description & Financial Analysis

8.4.2.2 SWOT Analysis

8.4.2.3 Products & Services Offered

8.4.2.4 Strategic Alliances between Business Partners

8.4.3        Bluebird bio

8.4.3.1 Business Description & Financial Analysis

8.4.3.2 SWOT Analysis

8.4.3.3 Products & Services Offered

8.4.3.4 Strategic Alliances between Business Partners

8.4.4        Bristol Myers Squibb

8.4.4.1 Business Description & Financial Analysis

8.4.4.2 SWOT Analysis

8.4.4.3 Products & Services Offered

8.4.4.4 Strategic Alliances between Business Partners

8.4.5        Atara Biotherapeutics

8.4.5.1 Business Description & Financial Analysis

8.4.5.2 SWOT Analysis

8.4.5.3 Products & Services Offered

8.4.5.4 Strategic Alliances between Business Partners

8.4.6        Allogene Therapeutics

8.4.6.1 Business Description & Financial Analysis

8.4.6.2 SWOT Analysis

8.4.6.3 Products & Services Offered

8.4.6.4 Strategic Alliances between Business Partners

8.4.7        Autolus Therapeutics  

8.4.7.1 Business Description & Financial Analysis

8.4.7.2 SWOT Analysis

8.4.7.3 Products & Services Offered

8.4.8.4 Strategic Alliances between Business Partners

8.4.8        Precision Biosciences, Inc.

8.4.8.1 Business Description & Financial Analysis

8.4.8.2 SWOT Analysis

8.4.8.3 Products & Services Offered

8.4.8.4 Strategic Alliances between Business Partners

8.4.9        Celyad Oncology

8.4.9.1 Business Description & Financial Analysis

8.4.9.2 SWOT Analysis

8.4.9.3 Products & Services Offered

8.4.9.4 Strategic Alliances between Business Partners

8.4.10      Cellectis

8.4.10.1 Business Description & Financial Analysis

8.4.10.2 SWOT Analysis

8.4.10.3 Products & Services Offered

8.4.10.4 Strategic Alliances between Business Partners

8.4.11      Other Companies

8.4.11.1 Business Description & Financial Analysis

8.4.11.2 SWOT Analysis

8.4.11.3 Products & Services Offered

8.4.11.4 Strategic Alliances between Business Partners

9          RESEARCH METHODOLOGY

9.1   Market Introduction

9.1.1        Market Definition

9.1.2           Market Scope & Segmentation

9.2   Information Procurement

9.2.1        Secondary Research

9.2.1.1 Purchased Databases

9.2.1.2 GMEs Internal Data Repository

9.2.1.3 Secondary Resources & Third Party Perspectives

9.2.1.4 Company Information Sources

9.2.2        Primary Research

9.2.2.1 Various Types of Respondents for Primary Interviews

9.2.2.2 Number of Interviews Conducted throughout the Research Process

9.2.2.3 Primary Stakeholders

9.2.2.4 Discussion Guide for Primary Participants

9.2.3        Expert Panels

9.2.3.1 Expert Panels Across 30+ Industry

9.2.4        Paid Local Experts

9.2.4.1 Paid Local Experts Across 30+ Industry Across each Region

9.3   Market Estimation

9.3.1        Top-Down Approach

9.3.1.1 Macro-Economic Indicators Considered

9.3.1.2 Micro-Economic Indicators Considered

9.3.2        Bottom Up Approach

9.3.2.1 Company Share Analysis Approach

9.3.2.2 Estimation of Potential Product Sales

9.4   Data Triangulation

9.4.1        Data Collection

9.4.2           Time Series, Cross Sectional & Panel Data Analysis

9.4.3        Cluster Analysis

9.5   Analysis and Output

9.5.1           Inhouse AI Based Real Time Analytics Tool

9.5.2           Output From Desk & Primary Research

9.6   Research Assumptions & Limitations

9.7.1        Research Assumptions

9.7.2        Research Limitations

LIST OF TABLES

1 Global Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Mllion)

2 Allogeneic Therapies Market, By Region, 2021-2029 (USD Mllion)

3 Autologous Therapies Market, By Region, 2021-2029 (USD Mllion)             

4 Others Market, By Region, 2021-2029 (USD Mllion)

5 Global Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Mllion)      

6 Hematologic Malignancies Market, By Region, 2021-2029 (USD Mllion)

7 Solid Tumors Market, By Region, 2021-2029 (USD Mllion)

8 Global Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Mllion)

9 Preclinical Market, By Region, 2021-2029 (USD Mllion

10  Clinical (Phase I, II, III) Market, By Region, 2021-2029 (USD Mllion)              

11 Commercialized Market, By Region, 2021-2029 (USD Mllion)          

12 Regional Analysis, 2021-2029 (USD Mllion)

13 North America Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

14 North America Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

15 North America Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

16 North America Next-Generation CAR T Cell Therapies Market, By Country, 2021-2029 (USD Million)

17 U.S Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

18 U.S Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

19 U.S Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

20 Canada Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

21 Canada Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

22 Canada Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

23 Mexico Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

24 Mexico Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

25 Mexico Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

26 Europe Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

27 Europe Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

28 Europe Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

29 Europe Next-Generation CAR T Cell Therapies Market, By country, 2021-2029 (USD Million)

30 Germany Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

31 Germany Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

32 Germany Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

33 U.K. Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

34 U.K. Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

35 U.K. Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

36 France Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

37 France Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

38 France Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

39 Italy Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

40 Italy Next-Generation CAR T Cell Therapies Market, By Targeted Indications , 2021-2029 (USD Million)

41 Italy Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

42 Spain Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

43 Spain Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

44 Spain Next-Generation CAR T Cell Therapies Market, By Development Phase , 2021-2029 (USD Million)

45 Lithuania Next-Generation CAR T Cell Therapies Market, By Type of Therapy, 2021-2029 (USD Million)

46 Lithuania Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

47 Lithuania Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

48 Estonia Next-Generation CAR T Cell Therapies Market, By Type of Therapy, 2021-2029 (USD Million)

49 Estonia Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

50 Estonia Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

51 Finland Next-Generation CAR T Cell Therapies Market, By Type of Therapy, 2021-2029 (USD Million)

52 Finland Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

53 Finland Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

54 Switzerland Next-Generation CAR T Cell Therapies Market, By Type of Therapy, 2021-2029 (USD Million)

55 Switzerland Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

56 Switzerland Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

57 Belgium Next-Generation CAR T Cell Therapies Market, By Type of Therapy, 2021-2029 (USD Million)

58 Belgium Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

59 Belgium Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

60 Poland Next-Generation CAR T Cell Therapies Market, By Type of Therapy, 2021-2029 (USD Million)

61 Poland Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

62 Poland Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

63 Netherlands Next-Generation CAR T Cell Therapies Market, By Type of Therapy, 2021-2029 (USD Million)

64 Netherlands Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

65 Netherlands Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

66 Ukraine Next-Generation CAR T Cell Therapies Market, By Type of Therapy, 2021-2029 (USD Million)

67 Ukraine Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

68 Ukraine Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

69 Sweden Next-Generation CAR T Cell Therapies Market, By Type of Therapy, 2021-2029 (USD Million)

70 Sweden Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

71 Sweden Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

72 Norway Next-Generation CAR T Cell Therapies Market, By Type of Therapy, 2021-2029 (USD Million)

73 Norway Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

74 Norway Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

75 Denmark Next-Generation CAR T Cell Therapies Market, By Type of Therapy, 2021-2029 (USD Million)

76 Denmark Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

77 Denmark Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

78 Rest Of Europe Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

79 Rest Of Europe Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

80 Rest of Europe Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

81 Asia Pacific Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

82 Asia Pacific Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

83 Asia Pacific Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

84 Asia Pacific Next-Generation CAR T Cell Therapies Market, By Country, 2021-2029 (USD Million)

85 China Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

86 China Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

87 China Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

88 India Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

89 India Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

90 India Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

91 Japan Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

92 Japan Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

93 Japan Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

94 South Korea Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

95 South Korea Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

96 South Korea Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

97 Singapore Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

98 Singapore Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

99 Singapore Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

100 Malaysia Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

101 Malaysia Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

102 Malaysia Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

103 Thailand Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

104 Thailand Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

105 Thailand Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

106 Indonesia Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

107 Indonesia Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

108 Indonesia Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

109 Vietnam Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

110 Vietnam Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

111 Vietnam Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

112 Taiwan Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

113 Taiwan Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

114 Taiwan Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

115 Rest of Asia Pacific Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

116 Rest of Asia Pacific Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

117 Rest of Asia Pacific Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

118 Middle East and Africa Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

119 Middle East and Africa Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

120 Middle East and Africa Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

121 Middle East and Africa Next-Generation CAR T Cell Therapies Market, By Country, 2021-2029 (USD Million)

122 Saudi Arabia Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

123 Saudi Arabia Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

124 Saudi Arabia Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

125 UAE Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

126 UAE Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

127 UAE Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

128 Israel Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

129 Israel Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

130 Israel Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

131 South Africa Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

132 South Africa Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

133 South Africa Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

134 Rest of Middle East and Africa Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

135 Rest of Middle East and Africa Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

136 Rest of Middle East and Africa Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

137 Central and South America Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

138 Central and South America Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

139 Central and South America Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

140 Central and South America Next-Generation CAR T Cell Therapies Market, By Country, 2021-2029 (USD Million)

141 Brazil Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

142 Brazil Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

143 Brazil Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

144 Argentina Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

145 Argentina Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

146 Argentina Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

147 Chile Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

148 Chile Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

149 Chile Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

150 Rest of Central and South America Next-Generation CAR T Cell Therapies Market, By Type of Therapy , 2021-2029 (USD Million)

151 Rest of Central and South America Next-Generation CAR T Cell Therapies Market, By Targeted Indications, 2021-2029 (USD Million)

152 Rest of Central and South America Next-Generation CAR T Cell Therapies Market, By Development Phase, 2021-2029 (USD Million)

153 NOVARTIS: Products & Services Offering

154 Kite Pharma (Tmunity Therapeutics): Products & Services Offering          

155 Bluebird bio: Products & Services Offering            

156 Bristol Myers Squibb: Products & Services Offering        

157 Atara Biotherapeutics: Products & Services Offering      

158 ALLOGENE THERAPEUTICS: Products & Services Offering     

159 AUTOLUS THERAPEUTICS : Products & Services Offering       

160 PRECISION BIOSCIENCES, INC.: Products & Services Offering            

161 Celyad Oncology, Inc: Products & Services Offering         

162 Cellectis: Products & Services Offering    

163 Other Companies: Products & Services Offering  

LIST OF FIGURES

1 Global Next-Generation CAR T Cell Therapies Market Overview

2 Global Next-Generation CAR T Cell Therapies Market Value From 2021-2029 (USD Mllion)

3 Global Next-Generation CAR T Cell Therapies Market Share, By Type of Therapy  (2023)

4 Global Next-Generation CAR T Cell Therapies Market Share, By Targeted Indications (2023)

5 Global Next-Generation CAR T Cell Therapies Market Share, By Development Phase (2023)

6 Global Next-Generation CAR T Cell Therapies Market, By Region (Asia Pacific Market)

7 Technological Trends In Global Next-Generation CAR T Cell Therapies Market

8 Four Quadrant Competitor Positioning Matrix

9 Impact Of Macro & Micro Indicators On The Market

10 Impact Of Key Drivers On The Global Next-Generation CAR T Cell Therapies Market

11 Impact Of Challenges On The Global Next-Generation CAR T Cell Therapies Market

12 Porter’s Five Forces Analysis

13 Global Next-Generation CAR T Cell Therapies Market: By Type of Therapy  Scope Key Takeaways

14 Global Next-Generation CAR T Cell Therapies Market, By Type of Therapy  Segment: Revenue Growth Analysis

15 Allogeneic Therapies Market, By Region, 2021-2029 (USD Mllion)

16 Autologous Therapies Market, By Region, 2021-2029 (USD Mllion)

17 Others Market, By Region, 2021-2029 (USD Mllion)

18 Global Next-Generation CAR T Cell Therapies Market: By Targeted Indications Scope Key Takeaways

19 Global Next-Generation CAR T Cell Therapies Market, By Targeted Indications Segment: Revenue Growth Analysis

20 Hematologic Malignancies Market, By Region, 2021-2029 (USD Mllion)

21 Solid Tumors Market, By Region, 2021-2029 (USD Mllion)

22 Global Next-Generation CAR T Cell Therapies Market: By Development Phase Scope Key Takeaways

23 Global Next-Generation CAR T Cell Therapies Market, By Development Phase Segment: Revenue Growth Analysis

24 Preclinical Market, By Region, 2021-2029 (USD Mllion)         

25 Clinical (Phase I, II, III) Market, By Region, 2021-2029 (USD Mllion)

26 Commercialized Market, By Region, 2021-2029 (USD Mllion)

27 Regional Segment: Revenue Growth Analysis

28 Global Next-Generation CAR T Cell Therapies Market: Regional Analysis

29 North America Next-Generation CAR T Cell Therapies Market Overview

30 North America Next-Generation CAR T Cell Therapies Market, By Type of Therapy  

31 North America Next-Generation CAR T Cell Therapies Market, By Targeted Indications

32 North America Next-Generation CAR T Cell Therapies Market, By Development Phase

33 North America Next-Generation CAR T Cell Therapies Market, By Country

34 U.S. Next-Generation CAR T Cell Therapies Market, By Type of Therapy  

35 U.S. Next-Generation CAR T Cell Therapies Market, By Targeted Indications

36 U.S. Next-Generation CAR T Cell Therapies Market, By Development Phase

37 Canada Next-Generation CAR T Cell Therapies Market, By Type of Therapy  

38 Canada Next-Generation CAR T Cell Therapies Market, By Targeted Indications

39 Canada Next-Generation CAR T Cell Therapies Market, By Development Phase

40 Mexico Next-Generation CAR T Cell Therapies Market, By Type of Therapy  

41 Mexico Next-Generation CAR T Cell Therapies Market, By Targeted Indications

42 Mexico Next-Generation CAR T Cell Therapies Market, By Development Phase

43 Four Quadrant Positioning Matrix

44 Company Market Share Analysis

45 Novartis: Company Snapshot

46 Novartis: SWOT Analysis

47 Novartis: Geographic Presence

48 Kite Pharma (Tmunity Therapeutics): Company Snapshot

49 Kite Pharma (Tmunity Therapeutics): SWOT Analysis

50 Kite Pharma (Tmunity Therapeutics): Geographic Presence

51 Bluebird bio: Company Snapshot

52 Bluebird bio: SWOT Analysis

53 Bluebird bio: Geographic Presence

54 Bristol Myers Squibb: Company Snapshot

55 Bristol Myers Squibb: Swot Analysis

56 Bristol Myers Squibb: Geographic Presence

57 Atara Biotherapeutics: Company Snapshot

58 Atara Biotherapeutics: SWOT Analysis

59 Atara Biotherapeutics: Geographic Presence

60 Allogene Therapeutics: Company Snapshot

61 Allogene Therapeutics: SWOT Analysis

62 Allogene Therapeutics: Geographic Presence

63 Autolus Therapeutics : Company Snapshot

64 Autolus Therapeutics : SWOT Analysis

65 Autolus Therapeutics : Geographic Presence

66 Precision Biosciences, Inc.: Company Snapshot

67 Precision Biosciences, Inc.: SWOT Analysis

68 Precision Biosciences, Inc.: Geographic Presence

69 Celyad Oncology, Inc.: Company Snapshot

70 Celyad Oncology, Inc.: SWOT Analysis

71 Celyad Oncology, Inc.: Geographic Presence

72 Cellectis: Company Snapshot

73 Cellectis: SWOT Analysis

74 Cellectis: Geographic Presence

75 Other Companies: Company Snapshot

76 Other Companies: SWOT Analysis

77 Other Companies: Geographic Presence

The Global Next-Generation CAR T Cell Therapies Market has been studied from the year 2019 till 2029. However, the CAGR provided in the report is from the year 2024 to 2029. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

Next-Generation CAR T Cell Therapies Market Size

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Next-Generation CAR T Cell Therapies Market.

Next-Generation CAR T Cell Therapies Market Growth

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Next-Generation CAR T Cell Therapies Market Trends

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.

Next-Generation CAR T Cell Therapies Market Share

We value your investment and offer free customization with every report to fulfil your exact research needs.
This website is secure and your personal details are safe. Privacy
You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The global next-generation CAR T cell therapies market is projected to grow at a CAGR of 33.1% from 2024 to 2029.
Novartis, Kite Pharma (Tmunity Therapeutics), Bluebird bio, Bristol Myers Squibb, Atara Biotherapeutics, Allogene Therapeutics, Autolus Therapeutics, Precision Biosciences, Inc., Celyad Oncology, and Cellectis., among others, are some of the key players operating in the global next-generation CAR T cell therapies market.
Opportunities in the global next-generation CAR T cell therapies market include enhanced safety profiles, expanded target antigen options, improved manufacturing processes for scalability, and potential applications in solid tumors. Additionally, advancements in gene editing technologies offer prospects for personalized treatments, fostering market growth and therapeutic efficacy.
The advancements in biotechnology and immunotherapy, increasing investment in research and development, expanding applications in oncology, rising prevalence of cancer, and growing collaborations between pharmaceutical companies and research institutions are the major drivers for global next-generation CAR T cell therapies market growth.

Tailor made solutions just for you

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

OUR CLIENTS

  • Client of Global Market Estimates - Fedex
  • Client of Global Market Estimates - Samsung
  • Client of Global Market Estimates - Siemens
  • Client of Global Market Estimates - Lonza
  • Client of Global Market Estimates - DuPont
  • Client of Global Market Estimates - Medtronic
  • Client of Global Market Estimates - Toray
  • Client of Global Market Estimates - Signify
  • Client of Global Market Estimates - Teledyne
  • Client of Global Market Estimates - Trelleborg
  • Client of Global Market Estimates - Kikkoman Biochemifa
  • Client of Global Market Estimates - Leoni
  • Client of Global Market Estimates - Molnlycke
  • Client of Global Market Estimates - Spirent
  • Client of Global Market Estimates - Tokyo Electron Limited
  • Client of Global Market Estimates - Aranca
  • Client of Global Market Estimates - Asahi Kasei
  • Client of Global Market Estimates - Chimai
  • Client of Global Market Estimates - Grapsud
  • Client of Global Market Estimates - Horiba
  • Client of Global Market Estimates - Indorama
  • Client of Global Market Estimates - L&T
  • Client of Global Market Estimates - Integralife
  • Client of Global Market Estimates - Synamedia
  • Client of Global Market Estimates - Sorrento Therapeutics
  • Client of Global Market Estimates - Solenis
  • Client of Global Market Estimates - Sartorius